Skip to content
Participate in our active studies
Subscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
Masitinib in oncology
Masitinib in viral diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
Severe Asthma
Prostate Cancer
Pancreatic Cancer
COVID-19
AB8939
News and Media
Press releases
In the Media
Webconference replay
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Search:
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
Masitinib in oncology
Masitinib in viral diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
Severe Asthma
Prostate Cancer
Pancreatic Cancer
COVID-19
AB8939
News and Media
Press releases
In the Media
Webconference replay
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Half-year reports
You are here:
Home
Investors
Regulated information
Half-year reports
2024
Half-year Financial Report
Half-year financial report as of June 30, 2024
2023
Half-year Financial Report
Half-year financial report as of June 30, 2023
2022
Half-year Financial Report
Half-year financial report as of June 30, 2022
2021
Half-year Financial Report
Half-year financial report as of June 30, 2021
2020
Half-year Financial Report
Half-year financial report as of June 30, 2020
2019
Half-year Financial Report
Half-year financial report as of June 30, 2019
2018
Half-year Financial Report
Half-year financial report as of June 30, 2018
2017
Half-year Financial Report
Half-year financial report as of June 30, 2017
2016
Half-year Financial Report
Half-year financial report as of June 30, 2016
2015
Half-year Financial Report
Half-year financial report as of June 30, 2015
2014
Half-year Financial Report
Half-year financial report as of June 30, 2014
2013
Half-year Financial Report
Half-year financial report as of June 30, 2015
2012
Half-year Financial Report
Half-year financial report as of June 30, 2012
2011
Half-year Financial Report
Half-year financial report as of June 30, 2011
2010
Half-year Financial Report
Half-year financial report as of June 30, 2010
Go to Top